Nuveen LLC Takes Position in Bruker Corporation $BRKR

Key Points

• Nuveen LLC has acquired a new stake in Bruker Corporation, purchasing 497,450 shares valued at approximately $20.76 million, representing 0.33% of the company.
• Bruker recently faced a missed earnings estimate of $0.32 EPS, compared to the consensus estimate of $0.33, with revenue down 0.4% year-over-year.
• The company has announced a quarterly dividend of $0.05 per share, with a current yield of 0.6% and a dividend payout ratio of 38.46%.

Nuveen LLC bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 497,450 shares of the medical research company's stock, valued at approximately $20,764,000. Nuveen LLC owned 0.33% of Bruker as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. CGN Advisors LLC boosted its holdings in Bruker by 1.4% in the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after buying an additional 296 shares during the last quarter. New York State Teachers Retirement System lifted its position in shares of Bruker by 0.8% in the first quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company's stock valued at $1,549,000 after acquiring an additional 300 shares in the last quarter. State of Michigan Retirement System boosted its stake in shares of Bruker by 1.1% in the first quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company's stock worth $1,106,000 after acquiring an additional 300 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Bruker by 1.0% during the first quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company's stock worth $1,294,000 after purchasing an additional 300 shares in the last quarter. Finally, KBC Group NV raised its stake in Bruker by 0.8% in the 1st quarter. KBC Group NV now owns 44,715 shares of the medical research company's stock valued at $1,866,000 after purchasing an additional 349 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Trading Up 5.1%

BRKR traded up $1.74 during trading hours on Friday, reaching $35.54. The company's stock had a trading volume of 1,939,915 shares, compared to its average volume of 3,459,438. The stock has a market cap of $5.39 billion, a PE ratio of 68.35, a P/E/G ratio of 2.79 and a beta of 1.16. Bruker Corporation has a fifty-two week low of $30.00 and a fifty-two week high of $72.94. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The business's 50-day moving average is $38.48 and its 200-day moving average is $41.05.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same period last year, the business earned $0.52 EPS. Bruker's revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker's payout ratio is 38.46%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Citigroup decreased their price objective on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Barclays decreased their price target on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. UBS Group dropped their price objective on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Finally, Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $51.30.

Insider Buying and Selling

In related news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is owned by insiders.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.